David Laurence Becker

Part of Thermo Fisher Scientific, Inc., Cell & Molecular Technologies, Inc. is a company that provides contract research, development services, and research products for biotech and pharmaceutical companies. The company is based in Phillipsburg, NJ. Cell & Molecular Technologies was acquired by Sentigen Holding Corp. on May 29, 1998 for $4.23 million.

CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand.

OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA.